First Time Loading...

Global Blood Therapeutics Inc
NASDAQ:GBT

Watchlist Manager
Global Blood Therapeutics Inc Logo
Global Blood Therapeutics Inc
NASDAQ:GBT
Watchlist
Price: 68.49 USD Market Closed
Updated: May 8, 2024

Global Blood Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Global Blood Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Global Blood Therapeutics Inc
NASDAQ:GBT
Revenue
$234.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$29.5B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
19%

See Also

What is Global Blood Therapeutics Inc's Revenue?
Revenue
234.9m USD

Based on the financial report for Jun 30, 2022, Global Blood Therapeutics Inc's Revenue amounts to 234.9m USD.

What is Global Blood Therapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
43%

Over the last year, the Revenue growth was 43%.